Genetic Polymorphism and CML Risk
Posted: Thursday, April 11, 2019
According to research published in the Asian Pacific Journal of Cancer Prevention, the risk of developing chronic myeloid leukemia (CML) is associated with a genetic polymorphism.
“Our results indicate that single nucleotide polymorphism in the gene involved in DNA base excision (OGG1 rs1052133) might play a crucial role in CML development and could play an important role in both an accelerated risk of CML and patient survival,” concluded Fathelrahman M. Hassan, PhD, of Bin Faisal University in Saudi Arabia. “The variants of this gene influence the predisposition to strengthen CML and worsen the prognosis of patients with DNA damage with this neoplasm.”
The study included 332 patients with CML and 70 patients who did not have CML, acting as a control group. The two groups were found to have significant variation in genotypes and alleles in the occurrence of the OGG1 rs1052133 polymorphism. Specifically, a statistically meaningful association was noted between the distribution of genotypes in the OGG1 rs1052133 polymorphism and patients with CML (P = .0000). In addition, a similar relationship was identified in the distribution of alleles (C vs. G, P = .0007) in patients with the OGG1 rs1052133 polymorphism who had CML when compared with those in the control group.
Disclosure: The study authors’ disclosure information may be found at journal.waocp.org.